Mounjaro's FDA approval for heart risk, explained

Mounjaro just got an important new cardiovascular indication — but the headline doesn't tell the whole story.

In this video, a pharmacist breaks down what actually changed for Mounjaro (tirzepatide), what the cardiovascular data showed, and what this could mean for certain adults with type 2 diabetes at increased cardiovascular risk.

The evidence comes from the SURPASS-CVOT cardiovascular outcomes trial, which compared Mounjaro with Trulicity (dulaglutide) — not placebo.

And there's an important detail that's easy to miss:

Mounjaro had an approximately 8% lower rate of MACE-3 cardiovascular events compared with Trulicity, while the trial established non-inferiority. But statistical superiority was not established.

So what does that actually mean?

We'll break down:

• What changed with Mounjaro
• What MACE-3 actually measures
• Why Trulicity was the comparator
• What “non-inferior” really means
• What the results do — and don't — prove
• How cardiovascular risk may now factor into treatment decisions

The goal isn't just to repeat the headline. It's to help you understand the evidence behind it.

• Medication Explained by a Pharmacist

If you find straightforward, evidence-based medication explanations helpful, subscribe for more videos covering GLP-1 medications, diabetes treatments, new FDA indications, medication safety, side effects, and major clinical-trial results.

IMPORTANT: This content is for educational purposes only and is not medical advice. Medication decisions should be individualized. Talk with your physician, pharmacist, or other qualified healthcare professional before starting, stopping, or changing a medication.